List of Excipients in Branded Drug IBUPROFEN LYSINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	IBUPROFEN LYSINE	ibuprofen lysine	66993-490	WATER

Generic Drugs Containing IBUPROFEN LYSINE

Company	Ingredient	NDC	Excipient
XGen Pharmaceuticals DJB Inc	ibuprofen lysine	39822-1030	WATER

What are the Most Frequently-Used Excipients in IBUPROFEN LYSINE?

# Of NDCs	Excipient
1	WATER

# Ibuprofen Lysine Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Ibuprofen lysine is an established NSAID salt with commercial potential in neonatal intravenous therapy, rapid-onset oral products, and differentiated liquid or multiparticulate formulations. The strongest opportunities are not in the active ingredient itself. They are in preservative-free sterile delivery, low-volume dosing, taste masking, rapid dissolution, pediatric usability, and manufacturing platforms that improve stability and supply reliability.

The commercial barrier is moderate. Ibuprofen lysine has an old active moiety, established clinical use, and multiple competing ibuprofen products. A defensible product requires a measurable formulation advantage, regulatory differentiation, or protected manufacturing process.

What is ibuprofen lysine and how does it differ from ibuprofen?

Ibuprofen lysine is the lysine salt of ibuprofen. It increases aqueous handling relative to free ibuprofen, which is a poorly water-soluble weak acid. The salt is used to support rapid dissolution and injectable dosage forms while delivering ibuprofen as the pharmacologically active moiety.

Attribute	Ibuprofen	Ibuprofen lysine
Drug class	NSAID	NSAID salt
Active moiety	Ibuprofen	Ibuprofen
Salt former	None	L-lysine
Solubility profile	Poorly water-soluble	Improved aqueous handling
Main dosage forms	Tablets, capsules, suspensions, gels	Injectable solutions, oral tablets, granules, liquids
Primary commercial use	Pain, fever, inflammation	Rapid-onset oral products and neonatal injection
Biosimilar pathway	Not applicable	Not applicable
Main regulatory pathway	Abbreviated or full NDA, depending on product	ANDA, 505(b)(2), or full NDA depending on formulation and claims

The lysine counterion does not create a new biologic product category. Ibuprofen lysine remains a small-molecule drug and is generally exposed to conventional generic competition rather than biosimilar competition.

What excipients are used in ibuprofen lysine products?

The excipient system depends on the dosage form. Injectable products require the narrowest formulation because premature infants and other vulnerable populations have limited tolerance for unnecessary excipients.

Injectable ibuprofen lysine

A neonatal injectable product should generally prioritize:

• Water for injection
• pH adjustment using hydrochloric acid or sodium hydroxide
• Tonicity adjustment where required
• Nitrogen headspace or oxygen-control measures if oxidation is material
• Low extractables and leachables packaging
• No antimicrobial preservative unless a clear multidose use case exists

The U.S. FDA labeling for NeoProfen identifies ibuprofen lysine equivalent to 10 mg/mL ibuprofen and describes a sterile injectable product for closure of clinically significant patent ductus arteriosus in premature infants [1]. The product is supplied in single-use vials, supporting a preservative-free strategy.

Arginine is used in some intravenous ibuprofen products, including products formulated with ibuprofen rather than ibuprofen lysine. It can improve solubilization and buffering but introduces additional material and compatibility considerations. A developer should not assume that the excipient profile of an adult intravenous ibuprofen product can be transferred directly to a neonatal ibuprofen lysine formulation.

Oral immediate-release tablets and capsules

Oral ibuprofen lysine products can use conventional excipients:

Functional requirement	Candidate excipient classes
Dilution and compressibility	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate
Lubrication	Magnesium stearate, sodium stearyl fumarate
Granulation	Povidone, hydroxypropyl cellulose
Flow control	Colloidal silicon dioxide
Taste or odor control	Film coat, sweetener, flavor, ion-exchange or lipid barrier
Moisture protection	Hypromellose film coat, polyvinyl alcohol coat, high-barrier blister

Ibuprofen lysine may support faster dissolution than free ibuprofen, but the product still requires control of granule porosity, compression force, lubricant level, and salt conversion. Excessive lubrication can reduce wetting and delay dissolution.

Oral liquids and pediatric suspensions

Pediatric liquids offer a larger excipient design space but also carry higher safety and palatability demands. Typical components include:

• Purified water
• Glycerin, sorbitol, or a mixed polyol system
• Suspending agents such as xanthan gum, microcrystalline cellulose with carboxymethylcellulose sodium, or hypromellose
• Buffering agents
• Sweeteners and flavors
• Chelating agents where justified
• Antimicrobial preservation for multidose packaging

A lysine salt can create a clear solution at a suitable concentration, but pH, ionic strength, taste, and osmolality may limit this approach. If the target concentration requires a suspension, the developer must control sedimentation, redispersibility, dose uniformity, and syringe withdrawal.

For children, the commercial advantage is strongest when the formulation combines low volume with acceptable taste. A 100 mg/5 mL product may be familiar, but a higher-strength product could reduce administration volume if dose uniformity and palatability remain acceptable.

Which excipient strategy is strongest for neonatal injection?

The strongest neonatal strategy is a minimal, preservative-free, single-use formulation with validated pH, particulate control, and container compatibility.

Key quality attributes

Critical quality attributes include:

• Ibuprofen lysine assay
• Ibuprofen-related impurities
• Lysine content or salt stoichiometry
• pH
• Osmolality
• Visible and subvisible particles
• Sterility
• Endotoxin
• Extractables and leachables
• Fill volume
• Container closure integrity
• Stability after dilution or preparation

Neonatal products face a narrow risk tolerance. Benzyl alcohol, parabens, phenolic preservatives, and high concentrations of certain surfactants are generally unattractive because of exposure concerns in premature infants. The FDA labeling for NeoProfen instructs preparation and administration under controlled conditions and identifies compatibility limitations with certain solutions and drugs [1].

A development program should test dilution into clinically used infusion fluids, adsorption to tubing, precipitation after admixture, and stability during the full preparation window. These studies can create a practical differentiation point even where the core drug is generic.

What formulations are commercially protectable?

The active ingredient and basic salt form are unlikely to provide durable exclusivity by themselves. Stronger protection can come from specific formulation and process limitations.

Formulation patents

Potential claim categories include:

1. A defined ibuprofen lysine concentration and pH range.
2. A preservative-free aqueous injection with specified impurity limits.
3. A formulation with controlled osmolality suitable for premature infants.
4. A high-strength oral solution with defined taste-masking agents.
5. A rapidly disintegrating tablet with specified dissolution performance.
6. A dry granule or sachet that forms a clear solution after reconstitution.
7. A multiparticulate formulation that separates ibuprofen lysine from incompatible excipients.
8. A formulation with improved stability under elevated temperature or humidity.
9. A container and closure system that limits oxygen or moisture ingress.
10. A specific dilution or administration method that reduces precipitation or adsorption.

Claims must be tied to measurable technical results. Generic claims covering ibuprofen lysine plus ordinary excipients are vulnerable to obviousness and lack-of-technical-effect challenges.

Method-of-use patents

Method-of-use opportunities are narrower because ibuprofen has extensive prior clinical use. Potential areas include:

• A defined neonatal dosing regimen
• Treatment of patent ductus arteriosus in a specified gestational-age population
• Use in patients with particular renal or gastrointestinal risk profiles
• Reduced-volume administration protocols
• A method that combines formulation-specific dosing with a defined infusion schedule

Method-of-use patents may be commercially relevant where an approved label supports a narrow indication, but generic substitution and skinny-label strategies can reduce their practical value.

When does ibuprofen lysine lose exclusivity?

Ibuprofen lysine does not have a single global exclusivity date. Exclusivity depends on the product, jurisdiction, formulation, listed patents, and regulatory status.

For the U.S. neonatal injectable market, NeoProfen was approved under NDA 021328. FDA product and labeling materials identify the product as ibuprofen lysine injection for premature infants with patent ductus arteriosus [1][2]. Public Orange Book analysis should be performed at the product level because discontinued, delisted, or expired listings can change the practical generic-entry assessment.

The underlying ibuprofen molecule and lysine salt chemistry are old. Any current barrier is therefore more likely to arise from:

• Product-specific formulation patents
• Manufacturing patents
• Container or delivery-system patents
• Regulatory exclusivity
• Supply and sterile-manufacturing qualification
• Clinical evidence required for a narrow neonatal indication

Exclusivity framework

Exclusivity type	Relevance to ibuprofen lysine
New chemical entity exclusivity	Generally unavailable for an old ibuprofen salt
Orphan-drug exclusivity	Possible only if statutory orphan criteria and designation requirements are met
Pediatric exclusivity	Possible as an extension of qualifying listed protections
Three-year clinical-investigation exclusivity	Possible for certain new formulations or indications supported by required clinical studies
Five-year NCE exclusivity	Not expected for ibuprofen lysine
Patent term	Depends on individual patent filing and grant dates
Regulatory data exclusivity outside the U.S.	Jurisdiction-specific

The relevant commercial question is not whether ibuprofen lysine is “protected” in the abstract. It is whether a competing applicant can obtain approval without infringing enforceable claims or relying on protected clinical data.

What is the Orange Book status of ibuprofen lysine?

The FDA Orange Book is the primary U.S. reference for approved drug products, therapeutic equivalence, patents, and exclusivity information [3]. NeoProfen should be reviewed by NDA number, dosage form, strength, and marketing status rather than by active ingredient alone.

A due-diligence review should confirm:

• Whether the reference listed drug remains active or has been discontinued
• Whether an ANDA can cite the product
• Whether a therapeutic-equivalence rating is available
• Whether patents remain listed
• Whether any exclusivity blocks approval
• Whether the proposed product qualifies for a 505(j) ANDA or requires a 505(b)(2) application

If no active listed patent or exclusivity remains, the commercial contest shifts toward bioequivalence, sterile manufacturing, supply reliability, hospital contracting, and formulary adoption.

Which companies are challenging ibuprofen lysine products?

The generic competitive field is fragmented because ibuprofen is widely manufactured, but ibuprofen lysine injection is a specialized sterile product. Competition may come from:

• Established injectable-drug manufacturers
• Pediatric and neonatal hospital suppliers
• Contract manufacturers with aseptic filling capability
• European suppliers of ibuprofen lysinate oral products
• Companies using conventional ibuprofen with alternative solubilization systems

Publicly visible Paragraph IV activity must be checked through FDA litigation records, the Orange Book, and court dockets. A Paragraph IV filing against a listed patent can trigger Hatch-Waxman litigation and, in some cases, a 30-month stay [4]. For an old active ingredient, the most likely Paragraph IV targets are formulation, manufacturing, or use patents rather than basic composition claims.

What manufacturing and IP barriers affect commercial entry?

Sterile injectable entry has a higher barrier than oral entry. The principal barriers are:

Aseptic manufacturing

The product requires validated sterilization, aseptic filling, container closure integrity, and particulate control. A developer may need a dedicated vial line or a qualified contract manufacturing organization. Small batch sizes can produce unfavorable unit economics.

Salt and pH control

Ibuprofen lysine may require tight control of salt stoichiometry, pH, concentration, and impurity formation. A process that appears simple at laboratory scale may develop precipitation, discoloration, or assay drift during storage.

Packaging

Glass vials, elastomeric stoppers, aluminum seals, and overwrap materials can affect oxygen exposure and leachables. A proprietary container system can support both a patent position and a regulatory differentiation strategy, but it also increases validation requirements.

Hospital preparation

A formulation that remains stable after dilution, minimizes line adsorption, and reduces preparation steps can compete effectively even without strong patent protection. These attributes can influence pharmacy purchasing and neonatal intensive-care unit protocols.

How does ibuprofen lysine compare with competing ibuprofen products?

Product type	Main advantage	Main weakness	Excipient opportunity
Conventional ibuprofen tablet	Low cost and mature supply	Slower dissolution and swallowing burden	Rapid-disintegration and low-dose-volume formats
Ibuprofen lysine tablet or sachet	Faster dissolution potential	Salt taste and hygroscopicity risk	Taste masking and moisture-protective packaging
Ibuprofen oral suspension	Pediatric usability	Sedimentation, preservation, and taste issues	High-strength, low-volume, sugar-reduced systems
Intravenous ibuprofen	Rapid systemic delivery	Sterile manufacturing cost	Preservative-free, low-volume, admixture-stable products
Neonatal ibuprofen lysine injection	Narrow clinical use and hospital value	Small market and high quality requirements	Ready-to-use vials, compatibility, and preparation simplicity

What are the commercial opportunities for excipient suppliers?

Excipient companies can capture value without owning the drug product by supplying differentiated systems.

High-value opportunities

• Taste-masking platforms for ibuprofen lysine liquids and granules
• Direct-compression excipient blends that preserve rapid dissolution
• High-barrier film coatings for moisture-sensitive salt products
• Preservative-free suspension systems
• Low-shear suspending systems with rapid redispersibility
• Oxygen-scavenging or low-permeability packaging
• Sterile-grade buffering and tonicity systems
• Ready-to-use neonatal injectable platforms
• Co-processed excipients for orally disintegrating tablets
• Reconstitution systems for pediatric sachets

The best commercial target is an excipient platform that solves a recognized development problem and can be used across multiple NSAID, analgesic, or pediatric products.

What revenue exposure and market risks should investors assess?

Ibuprofen is a high-volume, low-price molecule. Revenue exposure depends more on product format than on the active ingredient.

Higher-value segments

• Neonatal hospital injection
• High-strength pediatric products
• Rapid-onset oral products
• Branded over-the-counter products with differentiated packaging
• Combination products with strong consumer recognition

Lower-value segments

• Standard-strength generic tablets
• Unprotected ibuprofen capsules
• Commodity oral suspensions without a clear usability advantage

Key risks include price erosion, limited neonatal volume, hospital purchasing concentration, regulatory scrutiny of excipients, and substitution by conventional ibuprofen products. A sterile product can have better pricing than oral generics but also carries recall and manufacturing-continuity risk.

What is the strongest launch strategy for ibuprofen lysine?

A practical launch sequence is:

1. Select a defined clinical or usability problem, such as neonatal preparation complexity or pediatric dose volume.
2. Develop a minimal excipient system with a clear safety rationale.
3. Establish comparative dissolution, stability, palatability, or admixture data.
4. Determine whether the product fits an ANDA, 505(b)(2), or full NDA pathway.
5. Conduct Orange Book and global patent clearance before scale-up.
6. Protect the formulation, process, packaging, and administration method where the data support non-obvious technical effects.
7. Secure sterile capacity or a qualified contract manufacturer.
8. Build hospital, pediatric, or consumer distribution around the product’s measurable advantage.

Key Takeaways

• Ibuprofen lysine is an old small-molecule salt with limited prospects for basic composition-of-matter exclusivity.
• The most attractive excipient opportunities are in sterile neonatal injection, pediatric taste masking, rapid dissolution, and high-strength low-volume delivery.
• Preservative-free, single-use injectable formulations are the strongest fit for neonatal use.
• Oral products need protection against moisture, salt taste, compression-related dissolution loss, and dose-uniformity problems.
• Formulation, manufacturing, packaging, and method-of-use patents are more relevant than basic ibuprofen lysine claims.
• Ibuprofen lysine has no biosimilar market because it is a small molecule.
• Generic-entry risk is high for conventional oral products and moderate for specialized sterile products.
• The commercial winner will usually be the product with the best regulatory, manufacturing, and hospital-use profile rather than the lowest active-ingredient cost.

FAQs

Is ibuprofen lysine more soluble than ibuprofen?

Yes. The lysine salt improves aqueous handling and can support faster dissolution, although final performance depends on pH, particle properties, excipients, and dosage form.

Can ibuprofen lysine be formulated as a preservative-free oral liquid?

Yes. A single-use or unit-dose oral liquid can avoid preservatives, but the product must demonstrate microbiological control, physical stability, dose uniformity, and acceptable taste.

Does ibuprofen lysine require a biosimilar application?

No. Ibuprofen lysine is a small-molecule drug. Depending on the reference product and formulation, the U.S. pathway may be an ANDA, 505(b)(2), or full NDA.

What is the best excipient for masking ibuprofen lysine taste?

No single excipient is universally optimal. Film coating, lipid barriers, ion-exchange systems, sweetener-flavor combinations, and multiparticulate encapsulation should be selected based on dose, release profile, and pediatric exposure limits.

Can a new ibuprofen lysine formulation receive patent protection?

Yes, if the formulation, process, packaging, or use has patentable technical features and a defensible non-obviousness position. Broad claims covering ibuprofen lysine with routine excipients are less likely to provide durable protection.

References

1. U.S. Food and Drug Administration. (2006). NeoProfen (ibuprofen lysine) injection prescribing information. FDA.

2. DailyMed. (n.d.). NeoProfen: Ibuprofen lysine injection, solution. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman exclusivity and patent certification provisions. FDA.

5. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. ICH.

6. International Council for Harmonisation. (2005). Q9: Quality risk management. ICH.

7. International Council for Harmonisation. (2008). Q10: Pharmaceutical quality system. ICH.

8. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.